Ipamorelin: Complete Guide to Dosage, Mechanism, and the CJC-1295 Stack

What Is Ipamorelin?

Ipamorelin is a synthetic pentapeptide developed from research on growth hormone releasing peptides in the 1990s. It was first described by Novo Nordisk researchers in 1998 and is notable for being one of the most selective GHRPs identified. Where earlier GHRPs (GHRP-6, GHRP-2, hexarelin) produced GH release alongside significant cortisol and prolactin elevation, ipamorelin achieves comparable GH stimulation while leaving cortisol and prolactin largely unchanged at research doses.

The selectivity arises from its receptor binding profile. Ipamorelin binds the ghrelin receptor (GHSR-1a) with high affinity but its structural modifications reduce off-target activity at other pituitary receptors involved in ACTH/cortisol and prolactin release. This is the primary reason ipamorelin displaced GHRP-6 as the standard GHRP in research stacks: the cortisol-free GH release profile makes it more practical for extended research cycles without the immune-suppressive and catabolic consequences of elevated cortisol.

It should not be confused with sermorelin or CJC-1295, which are GHRH analogs acting on a different receptor. Ipamorelin and CJC-1295 operate through complementary mechanisms and are commonly combined for that reason, as described below.

Mechanism: How Ipamorelin Stimulates GH Release

Growth hormone is secreted by somatotroph cells in the anterior pituitary in pulses, not continuously. The pulse pattern is regulated by two opposing hypothalamic hormones: growth hormone releasing hormone (GHRH), which drives GH secretion, and somatostatin, which suppresses it. The ghrelin receptor provides a third pathway into this system.

When ipamorelin binds GHSR-1a in pituitary somatotrophs, it triggers intracellular calcium mobilization and protein kinase C activation, leading to GH exocytosis. This signal amplifies the magnitude of GH pulses that already occur naturally (it does not create entirely artificial pulses when somatostatin tone is high, which is one reason it produces more physiological-looking GH curves compared to supraphysiological exogenous HGH).

The GH released in response to ipamorelin then travels to the liver, where it stimulates IGF-1 production. IGF-1 mediates many of the anabolic and recovery effects attributed to GH axis activation: protein synthesis upregulation, satellite cell activation in muscle, collagen synthesis in connective tissue, and lipolysis in adipose tissue through GH receptor action. The GH pulse itself also acts directly on adipocytes to drive fatty acid release.

Ipamorelin Dosage and Administration

Standard dosing

The most commonly reported research range is 200-300 mcg per injection, administered 2-3 times daily. The short half-life of approximately 2 hours means single daily dosing produces only one GH pulse per day, while multiple daily doses produce multiple pulses and more sustained GH axis activation across the 24-hour period.

Timing rationale

The largest natural GH pulse in humans occurs during early slow-wave sleep, typically 60-90 minutes after falling asleep. Pre-sleep ipamorelin injection (30 minutes before bed, after a 2-3 hour fasted window) amplifies this natural pulse, which is why the pre-sleep injection is considered the highest-priority timing in most research protocols. If a researcher can only do one injection per day, pre-sleep is the consensus choice.

Morning fasted injection is the second most common timing because GH sensitivity is elevated after an overnight fast, and insulin is low (insulin strongly blunts GH pulsatility). Pre-workout injection is used to combine GH axis activation with exercise-driven GH release, which can produce an additive effect, though this is not uniquely established for ipamorelin versus other GHRPs.

Fasting window

Insulin is the primary physiological suppressor of GH secretion. Elevated insulin following a carbohydrate or protein meal sharply reduces pituitary somatotroph responsiveness. To maximize the GH response to ipamorelin, injections should be administered after a minimum 2-3 hour fast, and food should be avoided for at least 30-45 minutes post-injection. Fat intake has less impact on insulin than carbohydrate or protein, but most protocols advise complete fasting around injection windows for consistency.

Reconstitution

Ipamorelin is supplied as lyophilized powder, typically in 2 mg or 5 mg vials. Reconstitute with bacteriostatic water. A 2 mg vial with 2 mL of BAC water gives 1 mg/mL (1000 mcg/mL); a 200 mcg dose requires a 0.2 mL (20-unit) draw on an insulin syringe. Store reconstituted peptide at 2-8°C, used within 28-30 days. See the full reconstitution guide for sterile technique.

The CJC-1295 / Ipamorelin Stack

This combination is the dominant GHRH/GHRP stack in the research community. It works because CJC-1295 and ipamorelin act on two distinct, synergistic pathways within the pituitary:

• CJC-1295 binds the GHRH receptor (GHRH-R) on somatotrophs. The DAC (drug affinity complex) modification in CJC-1295 without DAC versus with DAC is a separate question (see the CJC-1295 dosage guide), but both forms increase the amplitude of GH pulses by preparing more somatotroph cells for release and extending the ready-to-release state.
• Ipamorelin binds GHSR-1a and triggers the GH release signal. It is the "trigger" to CJC-1295's "primer."

When administered together (or within a short window of each other), the combined GH response is substantially greater than either alone. Research suggests a synergistic rather than simply additive effect: CJC-1295 increases the pool of primed somatotrophs and ipamorelin simultaneously fires the release. The two are often co-administered in the same injection (mixed in the same syringe immediately before injection) or injected separately within minutes of each other. The standard combined dose in research is 100-200 mcg CJC-1295 + 200-300 mcg ipamorelin per injection, 1-2 times daily.

Ipamorelin vs Other GHRPs

GHRP-6 and GHRP-2 produce somewhat higher peak GH responses than ipamorelin at equivalent doses, but the cortisol and prolactin co-elevation is a meaningful drawback for extended research use. Elevated cortisol is catabolic to muscle tissue, blunts immune function, and interferes with recovery, which directly counteracts the intended anabolic and recovery goals of a GHRP research protocol. Hexarelin, the most potent GHRP, carries the additional issue of significant receptor desensitization, limiting practical cycle length.

Ipamorelin's lower desensitization profile is one of its most practical advantages. Research communities report cycles of 12-20 weeks without apparent attenuation of GH response, whereas GHRP-6 protocols more often include off periods at 8-12 week intervals due to receptor downregulation concerns.

Ipamorelin vs Sermorelin

These two peptides address GH axis enhancement from different receptor angles. Sermorelin is a truncated GHRH analog (29 of GHRH's 44 amino acids) that acts on the GHRH receptor. Ipamorelin is a GHRP acting on GHSR-1a. The two are not directly interchangeable; they are more accurately described as occupying different positions in the GH axis.

Sermorelin's shorter half-life (under 10 minutes) makes it more transient than CJC-1295 (which has modifications extending its half-life substantially). In practice, sermorelin was historically used in anti-aging clinics as a gentler, more physiological alternative to HGH, while ipamorelin emerged as the preferred GHRP for combining with CJC-1295 precisely because of its selectivity. See the full ipamorelin vs sermorelin comparison for detail on when each is preferred.

Cycle Length and Off Periods

Because ipamorelin produces low receptor desensitization, research cycles tend to be longer than with other GHRPs. Common patterns in the research community:

• 8-12 weeks on, 4 weeks off: Conservative protocol often used when combining with CJC-1295; the CJC-1295 DAC form's longer half-life means the GHRH receptor experiences more sustained stimulation, and periodic breaks prevent feedback axis blunting.
• 16-20 weeks continuous: Reported by researchers using lower doses (200 mcg once daily), particularly when the primary goal is sleep quality and recovery rather than aggressive GH axis amplification.
• Year-round at low dose: Some anti-aging protocols use ipamorelin at 100-150 mcg nightly with periodic 4-week breaks every 3-4 months. Less aggressive on the GH axis, more sustainable for general wellness goals.

The appropriate cycle length depends on dose, frequency, and combination with GHRH analogs. Higher-frequency dosing (3x/day with CJC-1295) warrants more conservative cycle structures than single daily pre-sleep dosing alone.

Expected Results and Timeline

Ipamorelin does not produce dramatic overnight changes. GH axis peptides work by gradually optimizing the GH pulse environment, which then takes additional weeks to manifest as measurable changes in body composition, sleep, and recovery. Realistic expectations from research community reports:

Ipamorelin as a standalone does not produce the dramatic body composition changes associated with exogenous HGH or anabolic steroids. It operates by optimizing the endogenous GH pulse environment, which is capped by pituitary capacity. When combined with CJC-1295, the effect is more pronounced because both arms of the GH secretory axis are engaged simultaneously.

Side Effects and Safety Profile

Ipamorelin's selectivity translates directly to its side effect profile. Compared to GHRP-6 and GHRP-2, the reported adverse effects are substantially milder and less frequent:

Common, typically transient

• Injection site reactions: Mild redness, tingling, or swelling at the SC injection site. Standard for any subcutaneous peptide injection. Rotating sites reduces occurrence.
• Water retention: A consequence of IGF-1 elevation. Typically mild (1-3 lbs of fluid, mostly in extremities). Resolves within a week or two at stable dose or on cessation.
• Mild hunger increase: Less pronounced than GHRP-6 but some ghrelin-mediated appetite stimulation occurs. More common in the first 2-4 weeks.
• Headache: Reported on the first few injections; typically self-limiting.

Uncommon

• Tingling in hands and feet: Associated with GH/IGF-1 elevation (carpal tunnel-adjacent effect at high doses). Dose-reduction resolves it in most cases.
• Fatigue: Occasional in the first week; may relate to altered sleep architecture as GH pulse patterns shift.

What ipamorelin does NOT typically cause

• Significant cortisol elevation (unlike GHRP-6 and GHRP-2)
• Significant prolactin or ACTH elevation
• Pronounced hunger spikes (unlike GHRP-6)
• Rapid receptor desensitization (unlike hexarelin)
• Suppression of natural GH production post-cycle (it amplifies rather than replaces the endogenous pulse; the axis typically recovers normally)

There are no formal long-term human safety studies on ipamorelin. The published animal research and Phase I/II clinical data (Novo Nordisk investigated ipamorelin for postoperative ileus, not GH axis indications) show a benign safety profile at doses studied, but long-term human data beyond research community self-reports is not available.

Where Ipamorelin Fits in the Broader GHRP Landscape

Among the research peptides targeting GH axis optimization, ipamorelin occupies the most practical middle ground: it is not the most potent GHRP (that is hexarelin), but its selectivity and tolerability make it the most commonly studied for extended research protocols. Its near-universal use in combination with CJC-1295 reflects a research consensus that the two-receptor approach (GHRH-R + GHSR-1a) produces a more complete and physiological GH secretory response than either alone.

For researchers interested in the full muscle-growth picture, ipamorelin/CJC-1295 is often layered with IGF-1 LR3 (direct IGF-1 receptor agonism downstream) or with MK-677 (ibutamoren), an oral ghrelin mimetic that activates the same receptor as ipamorelin but with a 24-hour half-life and different receptor kinetics. MK-677 and ipamorelin acting on the same receptor (GHSR-1a) means combining them at full doses produces diminishing returns; researchers typically use one or the other rather than stacking both at standard doses.